A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

This study is about learning more about a medicine called efgartigimod, which is used to treat a condition called generalized Myasthenia Gravis (gMG). gMG is a long-lasting condition that causes muscle weakness. This particular study is a bit different from typical research trials where new medicines are tested to see if they work. Instead, this study is happening after efgartigimod has already been approved for use, and its main purpose is to carefully watch patients as they take the medicine in their everyday lives.

The main aim is to understand the safety of efgartigimod when it's used by real patients in a real-world setting. This kind of study helps doctors and scientists gather more information about any possible side effects or how people react to the medicine over time, outside of strict clinical trial conditions. It helps ensure that new medicines continue to be safe and effective for everyone who needs them.

To do this, the study will involve two groups of people. One group will be patients with gMG who are either just starting efgartigimod or have recently started it. The other group will be patients with gMG who are not taking efgartigimod and don't plan to start it. By comparing these two groups, researchers can get a clearer picture of how efgartigimod affects patients' health and safety.